Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5958167 | 1.00 | GAA (0.40) | GAAG6PC1KMT2AMEN1HDAC8 | |
| SCHEMBL5957857 | 0.78 | G6PC1 (0.44) | G6PC1KMT2AMEN1MAPT | |
| SCHEMBL5957853 | 0.78 | G6PC1 (0.44) | G6PC1KMT2AMEN1MAPT | |
| SCHEMBL14667522 | 0.77 | G6PC1 (0.57) | GAAG6PC1KMT2AMEN1NPC1 | |
| SCHEMBL2615559 | 0.77 | G6PC1 (0.57) | GAAG6PC1KMT2AMEN1NPC1 | |
| SCHEMBL22203778 | 0.76 | CA2 (0.56) | GAAKMT2AMEN1HDAC8HDAC6 | |
| SCHEMBL9411079 | 0.75 | CA9 (0.40) | KMT2AFURINNPC1ALDH1A1MAPT | |
| SCHEMBL6346578 | 0.75 | CA9 (0.40) | KMT2AFURINNPC1ALDH1A1MAPT | |
| SCHEMBL6346576 | 0.75 | CA9 (0.40) | KMT2AFURINNPC1ALDH1A1MAPT | |
| SCHEMBL9788231 | 0.74 | LMNA (0.52) | GAAKMT2AMEN1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1577290-A1 | AMIDE COMPOUND AND METHOD OF CONTROLLING PLANT DISEASE WITH THE SAME | Sumitomo Chemical Company, Limited (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122065-A1 | Amide compound and method of controlling plant disease with the same | CBR3, C5, CLN6 | GAA 1809/4885G6PC1 4014/4885KMT2A 2654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.